IN PARTNERSHIP


A retrospective of the COVID-19 pandemic and its effects on clinical trials


The pandemic impacted not just trials but the supply chains that support them. Abacus Medicine Pharma Services reflects on how the sector adapted to the challenges of COVID-19 and what it has learned from it.


O


ne of the many casualties of the COVID-19 pandemic was the global clinical research industry. It caused


upheaval, with lockdown measures making  Many patients were reluctant to participate due to a fear of infection, which was particularly  Those still happy to participate became incapacitated as infection and mortality rates


12 | Clinical Trial Supply Handbook


grew. As a result of this, slow enrolment and high dropout rates caused delays in planned and ongoing studies, in some cases leading to cancellations. To continue the safe running of clinical  sponsors embraced a way of conducting trials remotely, where the medicine is sent directly to the patient’s home and data is collected through telemedicine and wearables.


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56